Pfizer (PFE) is showing signs of resurgence, outperforming the S&P 500 for the first time since 2022, as it appeals to investors seeking safety amid economic uncertainty. The stock has struggled over the past five years, declining 25% while the S&P 500 surged 68%. However, with a 6.4% dividend yield and a low forward price-to-earnings ratio of just over nine, Pfizer is becoming a more attractive option as market conditions shift.
Despite a modest 8% gain this year, Pfizer’s performance is noteworthy given the broader market’s 4% decline. Investors are increasingly drawn to dividend stocks during turbulent times, and Pfizer’s stable revenue of $62.6 billion—despite a slight operational decline—suggests resilience. The company’s recent acquisitions may provide a pathway for future growth, even as it navigates patent expirations and market challenges.
For market professionals, Pfizer presents a compelling opportunity: a heavily discounted stock with a strong dividend yield, offering a margin of safety in a volatile environment.
Source: fool.com